8 полученные результаты
CROSS-REFERENCE OF RELATED APPLICATION
This application is a National Stage Application of PCT/CN2015/083021, filed Jul. 1, 2015, which claims priority to Chinese Patent Application No. 201410353810.5, filed Jul. 23, 2014 and Chinese Patent Application No. 201410497974.5, filed Sep. 25, 2014, the
COPYRIGHT NOTICE/PERMISSION
A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and
COPYRIGHT NOTICE/PERMISSION
A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and
BACKGROUND
1. Technical Field
The invention is in the fields of drug therapy; more specifically, the invention encompasses a protein for immunosuppression.
2. The Prior Art
The central nervous system (CNS) actively maintains immune privilege (Carson and Sutcliffe, 1999; Fabry et al., 1994), in part
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the manufacture and use of recombinant albumin fusion proteins to make human interferon analogs. The novel interferon analogs have the same functions with interferon in bio-assays, in vitro or in vivo. These long acting
TECHNICAL FIELD
The present disclosure is in the field of genome engineering.
BACKGROUND
Gene therapy holds enormous potential for a new era in human medicine. These methodologies will allow treatment for conditions that heretofore have not been addressable by standard medical practice. One area
BACKGROUND OF THE INVENTION
Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in the above-referenced patent applications relating to novel anti-IL-6 antibodies, novel therapies and therapeutic protocols utilizing anti-IL-6 antibodies, and pharmaceutical
The sequence listing in the file named "56256o2006.txt" having a size of 332,224 bytes that was created Sep. 26, 2017 is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in the